Navigation Links
Dornier Lithotripter S II

ProductsDornier Lithotripter S II
Company Dornier MedTech
Item Dornier Lithotripter S II
Features 
  • Latest generation Dornier EMSE 220f
  • Broad range of energy levels
  • Easy to move therapy head
  • Optimal system integration and compatibility
  • Easy patient access with little or no assistance
  • Simple stone positioning
  • 50 Kw high frequency X-ray generator
  • Digital image, printing and archival
  • Documentation monitoring
Description The Dornier Lithotripter S II is ideally suited for high volume stone centers. This lithotripter is both an excellent stone therapy system and an advanced urological table. With the Dornier EMSE-based shock wave source, the DoLi S II provides successful treatments for a full range of calculi. Due to its flexible table design, conducting URS and PCN procedures are easy. One of the most outstanding features of the DoLi S II is the dual imaging principle. This is accomplished by adding the optional ultrasound system with X-ray during stone therapy. The X-ray function can be used to pre-position and localize the stone before switching to ultrasound to monitor the treatment progress.
Info Dornier MedTech
Customer Service: (800) 367-6437
Web site: http://www.dornier.com/index.html

Related medicine products :

1. Dornier Medilas D Fibertom Endovenous Laser Treatment
2. Dornier Holmium Laser for Urological Procedures
3. Dornier Compact Delta
4. Dornier Compact Sigma
... an innovative handheld device for ... non-invasively, comfortably, and accurately.,It is, ... than an automatic blood pressure ... charge, Vasotrax will take approximately ...
... Insulin-like growth factor II (IGF-II) is a 7.5 ... liver and is postulated to have mitogenic and ... of IGF-II are mediated by binding to target ... the Type II IGF receptor, a monomeric protein ...
... Pregnancy-associated plasma protein A (PAPP-A) is ... is produced in high concentrations by ... into the maternal circulation in increasing ... PAPP-A is not specific to pregnancy ...
... Pregnancy-associated plasma protein A (PAPP-A) ... PAPP-A is produced in high concentrations ... released into the maternal circulation in ... [1]. PAPP-A is not specific to ...
Medicine Products:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: